Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBT-001 in Primary or Recurrent Pterygium
NCT03049852Phase 2Completed
- Sponsor
- Cloudbreak Pharma
- Start
- Apr 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of STN1014200 in pterygium (3 arms), sponsored by Cloudbreak Pharma. Primary endpoints: Pterygium Vascularity Change Assessed Using the Pterygium Hyperemia Grading Scale at 4 weeks and Ocular and General Safety and Tolerability at 1 day. Started Apr 2017; status: completed.
02
Drugs
STN1014200
03
Conditions
pterygium
Beyond the preview
Go deeper on NCT03049852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03049852.